What does Antares Therapeutics do?
Antares Therapeutics is a Boston-based biotechnology company focused on developing precision medicines targeting validated, undruggable targets in cancer and other serious diseases with large unmet needs. It is a spin-out of Scorpion Therapeutics with an experienced leadership team.
How much did they raise?
The company raised $177M in a Series A funding round led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with additional participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors.
What are their plans for the money?
The funds will be used to expand operations and enhance R&D efforts, with plans to advance its precision medicine candidates towards clinical trials, including an advanced program expected to enter the clinic by 2026.
What have they achieved so far?
Antares Therapeutics has already progressed several programs in preclinical development and benefits from its successful origins as a spin-out, following the sale of Scorpion Therapeutics’ PI3Kα inhibitor program to Eli Lilly in a landmark deal.
